Stem cell therapy for spinal cord injury: Lessons from Japan's experiment in regulatory deregulation.

No abstract is available for this paper.

• Publication year

  2026

• Venue

  The spine journal

• Publication date

  2026-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.spinee.2026.01.005PMID 41512928
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dark Clouds Looming Over Regenerative Medicine in Japan

  2025cited by this paper
• Stem cell therapies for spinal cord injury in humans: A review of recent clinical research

  2025cited by this paper
• Too little, too soon: Japan's experiment in regenerative medicine deregulation.

  2023cited by this paper
• Hope for the best, but prepare for the worst: Social media posted by participants in stem cell clinical trials

  2023cited by this paper
• Mesenchymal Stem Cell Therapy in Traumatic Spinal Cord Injury: A Systematic Review

  2023cited by this paper
• Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series.

  2021cited by this paper
• Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords

  2021cited by this paper
• The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines

  2021cited by this paper
• Characterizing Natural Recovery after Traumatic Spinal Cord Injury

  2020cited by this paper
• Japan’s approval of stem-cell treatment for spinal-cord injury concerns scientists

  2019cited by this paper
• Misrepresentation and distortion of research in biomedical literature

  2018cited by this paper
• Social media and clinical trials: The pros and cons gain context when the patient is at the center

  2018cited by this paper
• Stem the tide

  2015cited by this paper
• A Systematic Review of Cellular Transplantation Therapies for Spinal Cord Injury

  2011cited by this paper
• A Phase I/IIa Clinical Trial of a Recombinant Rho Protein Antagonist in Acute Spinal Cord Injury

  2011cited by this paper
• Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures

  2007cited by this paper
• Coverage by the news media of the benefits and risks of medications.

  2000cited by this paper

• No citing papers are available for this paper.